Posts

Recent Pharma News: Novo Nordisk's Oral Semaglutide for Kids, Altimmune $225M Offering, Merck-Google Cloud Partnership

on

Novo Nordisk Partners with OpenAI to Accelerate Drug Development

on

Ambrosia Raises $100M Series B to Develop Next-Generation Small Molecule GLP-1s

on

Novo Nordisk's Triple-G Agonist UBT251 Achieves 19.7% Weight Loss in Phase 2 Trial in China

on

Novo Nordisk Refocuses on Diabetes and Obesity to Expand GLP-1 Market at JPM26

on

Novo Nordisk Ups Metsera Bid to $10 Billion to Top Pfizer's Offer

on

Novo Nordisk Ends Cell Therapy Research Amid Major Restructuring

on

Eli Lilly to Invest Over $1 Billion to Expand Manufacturing Footprint in India

on

Novo Nordisk Terminates $598M Heart Failure Cell Therapy Collaboration with Heartseed Amid Major Restructuring

on

Sanofi Expands $35 Insulin Program to All U.S. Patients Nationwide

on

Personalizing Metabolic Care with Digital Twins: Recent Developments

on

Execution, Execution, Execution: Novo's New CEO Doubles Down on Obesity, Diabetes and Trims Pipeline

on

BrightGene's BGM0504 Outperforms Novo Nordisk's Semaglutide in Diabetes Trial, Eyes Showdown with Zepbound

on

Diabetes and Obesity Drug Boom to Propel Lilly and Novo Nordisk to Pharma Sales Leadership by 2030: Evaluate

on

Schott Pharma Invests Over €100M in New Sterile Cartridge Facility at Hungary Site

on

Chronic care startup Omada Health files to go public

on

Novo Nordisk Invests $1.1 Billion to Expand GLP-1 Drug Manufacturing in Brazil

on

Axplora Invests €50M in GLP-1 Manufacturing Expansion at Mourenx, France

on

FDA Approves Ozempic for Reducing Kidney Disease Risks in Adults with Type 2 Diabetes and Chronic Kidney Disease

on